Skip to main content

Table 4 Predictors of 30- day Mortality in octogenarians treated with MVS vs. MC

From: Clinical outcomes of conventional surgery versus MitraClip® therapy for moderate to severe symptomatic mitral valve regurgitation in the elderly population: an institutional experience

 

univariate Cox Regression

 

all Patients (n = 84)

MVS (n = 42)

MC (n = 42)

Variable

Hazard Ratio

95%-CI

p-value

Hazard Ratio

95%-CI

p-value

Hazard Ratio

95%-CI

p-value

Logistic Euroscore

  > 10 vs. <=10a

**

**

**

**

**

**

**

**

**

NYHA baseline

 class 3/4 vs. class 1/2a

**

**

**

**

**

**

**

**

**

Baseline LVEF

  > 50% vs. <=50%a

1.07

0.07–17.1

0.963

**

**

**

1.18

0.07–18.9

0.905

Cardiac decompensation

 yes vs. noa

**

**

**

**

**

**

**

**

**

Age

 80–82 years vs. 83–85 yearsa

**

**

**

**

**

**

**

**

**

Sex

 female vs. malea

1.11

0.16–7.85

0.920

**

**

**

**

**

**

Coronary artery disease

 yes vs. noa

1.44

0.15–13.8

0.753

**

**

**

0.60

0.04–9.53

0.714

Diabetes mellitus

 no vs. yesa

1.82

0.19–17.5

0.604

**

**

**

0.77

0.05–12.3

0.851

COPD

 yes vs. noa

7.26

0.76–69.9

0.086

2.85

0.18–45.6

0.459

**

**

**

GFR ≤ 30

 yes vs. noa

**

**

**

**

**

**

**

**

**

GFR 30–50

 yes vs. noa

1.77

0.25–12.5

0.570

**

**

**

**

**

**

Atrial fibrillation

 yes vs. noa

1.68

0.17–16.1

0.655

0.71

0.04–11.4

0.810

**

**

**

Pulmonary hypertension

 yes vs. noa

**

**

**

**

**

**

**

**

**

  1. **not determinable, because there are only censored times
  2. aindicates reference category